Halozyme Therapeutics, Inc.

Halozyme Therapeutics, Inc. is a biopharmaceutical company that researches, develops, and commercializes proprietary enzymes and devices globally. Its core technology is based on the patented recombinant human hyaluronidase enzyme (rHuPH20), which enables the delivery of injectable biologics such as monoclonal antibodies and therapeutic molecules, as well as small molecules and fluids. The company offers several products, including Hylenex recombinant, which facilitates subcutaneous administration to enhance drug dispersion and absorption; XYOSTED, an injection for testosterone replacement therapy; and Herceptin Hylecta for breast cancer. Halozyme also has a portfolio of partnered products like Phesgo, Mabthera SC, Tecentriq SC, Ocrevus SC, HYQVIA, DARZALEX, and others used to treat various conditions including cancer, multiple sclerosis, immunodeficiency disorders, and autoimmune diseases.

Halozyme Therapeutics, Inc. is listed on the Nasdaq Global Select Market (NasdaqGS) under the ticker symbol HALO. The company trades in United States Dollars (USD), as it is headquartered in the United States. The exchange is one of the major US stock exchanges, providing liquidity and visibility for the company's shares.

Halozyme Therapeutics operates in the Healthcare sector, specifically within the Biotechnology industry. As a biotechnology company, it focuses on developing innovative therapies using enzyme technology. Its primary area of expertise is the use of recombinant human hyaluronidase to improve the delivery of injectable drugs, which positions it within the biopharmaceutical subsector of healthcare.

Halozyme's key products include Hylenex recombinant, XYOSTED, and Herceptin Hylecta. The company also has a broad portfolio of partnered products developed through collaborations with major pharmaceutical companies. These partnerships include agreements with F. Hoffmann-La Roche, Ltd. and Hoffmann-La Roche, Inc. for products like Phesgo, Mabthera SC, Tecentriq SC, and Ocrevus SC; Takeda Pharmaceuticals and Baxalta for HYQVIA; Janssen Biotech for DARZALEX; Pfizer for epinephrine injection; AbbVie for nivolumab and relatlimab; Eli Lilly for teriparatide injections; and Bristol Myers Squibb for ARGX-113 and ARGX-117. These partnerships allow Halozyme to leverage its enzyme technology across a wide range of therapeutic areas.

Halozyme's business model revolves around the research, development, and commercialization of proprietary enzymes, primarily its recombinant human hyaluronidase (rHuPH20) technology. The company generates revenue through the sale of its own products, such as Hylenex recombinant and XYOSTED, as well as through licensing and collaboration agreements with other pharmaceutical companies. Under these agreements, Halozyme typically receives upfront payments, milestone payments, and royalties on sales of partnered products that utilize its enzyme technology. This model allows Halozyme to benefit from the commercial success of a diverse range of injectable biologics and therapeutics developed by its partners, covering indications from oncology to immunology and endocrinology.